Table 3.
Correlation of CD98hc expression with clinical outcomes in patients with malignant diseases (exemplary studies).
| Tumor entity | Analysis | Treatment | Patient number | Significant association with clinical endpoints and additional parameters | References |
|---|---|---|---|---|---|
| NSCLC with resectable N1 and N2 LN metastases | IHC | SURG, SURG +RT, SURG +CT | 220 | Postoperative survival | (38) |
| NSCLC | IHC | SURG | 241 | DFS; OS; Co-expression with CD147; TNM stage; tumor diameter |
(55) |
| HPV-positive OPSCC | IHC | SURG + RT, RT, CRT, RT + LND + RT (brachytherapy) | 711 | OS; PFS | (37) |
| HNSCC | IHC | PORT-C, RCTx | 197 | LRC; LAT1 expression |
(11) |
| NanoString RNA analyses | RCTx | 158 | LRC | (43) | |
| HNSCC, HPV16 DNA negative | RT-PCR and NanoString technology | cisplatin-based PORT-C | 195 | LRC; Distant metastases |
(155) |
| Gastric cancer | IHC | SURG | 331 | OS; PFS; tumor stage; LN metastasis; vascular invasion | (117) |
| Breast cancer (TNBC & non-TNBC) | IHC | SURG | 78 (TNBC) 202 (non-TNBC) |
OS; DFS | (36) |
| Invasive breast cancer | IHC, DNA/RNA profiling | SURG, CT for ER-negative and LN-positive patients | 1858 | DFS in TNBC; DFS in ER+ high-proliferation tumors; SLC7A5 expression; SLC7A11 expression; TP53 mutations; ER− and PR− status; High expression in TNBC; high Ki67staining |
(151) |
| CRC | IHC | SURG | 147 | OS; DFS; T factor (T1-2/T3-4); Lymphatic permeation; Vascular invasion; LAT1 expression; Ki67 staining |
(154) |
| PPC | IHC | SURG | 105 | OS; DFS; T factor (T1-2/T3-4); Pathological stage: I-II/III-IV; LAT1 expression |
(148) |
CRC, colorectal cancer; CRT, chemoradiation; CT, chemotherapy; DFS, disease-free survival; ER, estrogen receptor; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IHC, immunohistochemistry; LN, lymph nodes; LND, lymph node dissection; LRC, locoregional control; NSCLC, non-small-cell lung cancer; OPSCC, oropharyngeal squamous cell carcinoma; PFS, progression-free survival; PORT-C, postoperative radio(chemo)therapy; PPC, pulmonary pleomorphic carcinoma; PR, progesterone receptor; RCTx, primary radiochemotherapy; RT, radiotherapy; SURG, surgery, TNBC, triple-negative breast cancer; TNM, tumor (T), nodes (N), and metastases (M); OS, overall survival.